Background There is no standard first-line chemotherapy for advanced urothelial carcinoma
(aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and …

Background The present study (VINGEM) is the first randomised trial comparing
vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with …

Purpose We comprehensively reviewed current efforts and advances in the field of
chemotherapeutic and biologically targeted treatment options after the failure of cisplatin …

Background To compare long-term, updated overall survival (OS) of patients with advanced
transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine plus best …

BACKGROUND: The activity and safety of vinflunine was evaluated in patients with locally
advanced or metastatic urothelial carcinoma (UC) who developed disease progression …

Background Vinflunine is recommended in the European guideline for the treatment of
advanced or metastatic urothelial cell carcinoma (UCC) after failure of platinum-based …

5028 Background: Second line therapy in TCCU is an unmet medical need. V is a new
microtubule inhibitor that has shown in phase II trials to be active against TCCU (Culine S …

Objective: The objective of this retrospective study was to investigate the efficacy and safety
of vinflunine monotherapy and the utility of second-line prognostic factors in patients with …

We are more than two decades removed from the heady days of the mid-1980s when hope
that the unprecedented activity seen in advanced testes cancer by the cisplatin, vinblastine …

Background Patients with transitional cell carcinoma of the urothelial tract (TCCU) who fail
initial platinum-based chemotherapy for advanced disease represent a challenge in daily …